Does CYP2C19*17 carrier status affect platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement?
The CYP2C19*17 allelic variant identifies patients at an increased risk of bleeding and enhanced pharmacodynamic response when treated with clopidogrel after coronary stenting.
CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding.
Sibbing et al. (Tue,) studied this question.